Welcome to our dedicated page for CDT Equity news (Ticker: CDT), a resource for investors and traders seeking the latest updates and insights on CDT Equity stock.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company whose news flow reflects its focus on AI-enabled drug repurposing, solid-form chemistry, and capital-efficient asset development. Originally operating as Conduit Pharmaceuticals Inc., the company has reported a series of strategic updates as it reshapes itself into a platform centered on high-potential therapeutic assets and intellectual property-led partnerships.
News about CDT often highlights progress in its clinical and pre-clinical programs, particularly around glucokinase activators such as AZD1656 and AZD5658. The company has announced AI-driven discoveries of new biological targets and indications, pre-clinical study results that support these findings, and the filing of new patent applications for key assets and combinations. These items provide insight into how CDT uses artificial intelligence and algorithmic analysis to expand the potential uses of existing compounds.
Another recurring theme in CDT’s news is collaboration. Press releases describe partnerships with Sarborg for AI-powered disease mapping and diagnostic tools, and a joint development agreement with Manoira to evaluate AZD1656 and AZD5658 in animal health indications. Updates on these collaborations can include study plans, cross-species data generation, and implications for both human and veterinary applications.
CDT also issues news on corporate and financial developments. Examples include the adoption and execution of a cryptocurrency-based treasury reserve strategy focused on Bitcoin, board decisions on reverse stock splits, and governance matters documented in SEC-related announcements. Together, these updates offer a view into how the company manages its capital structure while pursuing IP-led licensing and out-licensing opportunities.
Investors and observers who follow CDT’s news can monitor developments in its AI-guided pipeline, patent portfolio, partnerships, and treasury strategy, all of which are central to the company’s stated goal of advancing and monetizing biopharmaceutical assets.
CDT Equity (Nasdaq: CDT) filed two patent applications on March 26, 2026, expanding its tapinarof intellectual property portfolio.
One patent covers a tapinarof combination therapy with a class of drugs used in psoriasis and atopic dermatitis; the other covers novel tapinarof cocrystal forms. CDT says these filings may support a second-generation product, extend lifecycle, broaden clinical scope, and enable out-licensing opportunities.
CDT Equity (Nasdaq: CDT) announced a 1-for-25 reverse stock split effective March 26, 2026 at 5:00 pm ET, with shares expected to trade on a split-adjusted basis on Nasdaq at market open on March 27, 2026. As a result, every 25 issued and outstanding shares will combine into one share, reducing outstanding shares to approximately 4,722,450.
Par value remains $0.0001. Proportional adjustments apply to equity awards, convertible securities, warrants, and shares reserved under equity incentive plans. No fractional shares will be issued; cash payments will be made instead. The new CUSIP will be 20678X502.
CDT (Nasdaq: CDT) completed initial signature mapping of its asset portfolio against Sarborg's AI-curated rare disease database, identifying multiple statistically significant matches across immunology, oncology, infectious disease, paediatric and ophthalmology.
The analysis evaluated CDT assets including its solid-form patent portfolio and licensed AstraZeneca compounds AZD1656 and AZD5658 against about 1,700 rare-disease signatures. CDT plans targeted preclinical validation to build out datasets for early-stage out-licensing discussions.
CDT Equity (Nasdaq: CDT) announced stockholders approved all proposals at the Special Meeting held March 17, 2026. Key highlights include a $123M investment in Sarborg, expansion of the company IP portfolio, potential access to new capital, and a targeted annual overhead of less than $8 million.
The company says its AI-driven platform can analyze more than 3,000 diseases in hours versus conventional timelines, and CDT is shifting toward out-license deals with disease-specific partners and funds.
CDT (Nasdaq: CDT) announced a collaboration with Sarborg to map CDT’s asset portfolio, including combination therapies, against Sarborg’s expanded rare disease signature database of approximately 1,700 signatures.
CDT holds a 20% equity stake in Sarborg and intends to use the data to strengthen its IP position and explore external commercialization opportunities.
CDT (Nasdaq: CDT) notes Sarborg Limited filed a U.S. provisional patent application for its AI Signature Agent on February 12, 2026, assigned U.S. Application No. 63/981,801.
CDT holds a 20% equity stake in Sarborg and says the filing strengthens Sarborg’s IP position for its Signature Agent architecture that encodes and analyses biological, chemical and industrial signatures.
CDT (Nasdaq: CDT) announced strategic moves to expand its pharmaceutical portfolio and completed a 20% equity acquisition in Sarborg for $115 million, paid via common stock and pre-funded warrants. The company is advancing solid-form and cocrystal programs and managing licensed assets AZD1656, AZD5658 and AZD5904.
CDT says it is evaluating out-licensing, partnerships, and capital markets options to maximize asset value and enhance financial flexibility for potential transformative transactions.
CDT (Nasdaq: CDT) notes Sarborg Limited's expansion of its AI Signature Agent platform beyond pharmaceuticals into bacteria and agrochemicals. CDT holds a 20% equity stake in Sarborg. Sarborg has curated ~4,500 agrochemical and ~1,600 bacterial signatures, supporting multi‑sector scaling.
CDT says this extension broadens Sarborg's addressable markets and gives public investors exposure to its private AI signature intelligence development.
CDT (Nasdaq: CDT) agreed to acquire a 20% equity stake in Sarborg, an agentic AI signature intelligence business, for $115,000,000 settled via issuance of 598,005 new common shares and 109,978,918 pre-funded warrants, subject to shareholder approval. A further $8,000,000 deferred payment is payable upon completion of future fundraising. The deal deepens an existing collaboration focused on signature-led analysis and solid-form intellectual property, expanding CDT’s exposure beyond pharmaceuticals and aligning strategic capabilities between the companies.
CDT (Nasdaq: CDT) announced on January 2, 2026 that it has engaged NJS Foresight Bio-Advisory to identify, source and support execution of out-licensing opportunities for selected assets in its solid-form patent portfolio.
The engagement leverages NJS Foresight's >20 years of out-licensing experience and principal Dr. Nicholas J. Sarlis's clinical and pharma background. CDT's solid-form portfolio includes cocrystals and salts designed to improve solubility, bioavailability and delivery modes and carries up to 20 years of patent protection, enabling potential lifecycle extension for marketed products facing patent cliffs.
CDT said it will target licensing and royalty transactions as companies respond to patent expirations, consolidation and AI-driven adoption across biopharma.